<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Hu Z</submitter><funding>American Cancer Society</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><pubmed_abstract>Microtubule-associated protein tau is essential for microtubule assembly and stabilization. Hyperphosphorylation of the microtubule-associated protein tau plays an important pathological role in the development of Alzheimer's disease and other tauopathies. &lt;i>In vivo&lt;/i> studies using kinase inhibitors suggest that reducing tau phosphorylation levels has therapeutic potential; however, such approaches showed limited benefits. We sought to further develop our phosphorylation targeting chimera (PhosTAC) technology to specifically induce tau dephosphorylation. Herein, we use small molecule-based PhosTACs to recruit tau to PP2A, a native tau phosphatase. PhosTACs induced the formation of a stable ternary complex, leading to rapid, efficient, and sustained tau dephosphorylation, which also corr</pubmed_abstract><journal>Journal of the American Chemical Society</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11670127</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.</pubmed_title><pmcid>PMC11670127</pmcid><funding_grant_id>R35 CA197589</funding_grant_id><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Chen PH</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Hu Z</pubmed_authors><pubmed_authors>Crews CM</pubmed_authors><pubmed_authors>Douglas T</pubmed_authors><pubmed_authors>Hines J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.</name><description>Microtubule-associated protein tau is essential for microtubule assembly and stabilization. Hyperphosphorylation of the microtubule-associated protein tau plays an important pathological role in the development of Alzheimer's disease and other tauopathies. &lt;i>In vivo&lt;/i> studies using kinase inhibitors suggest that reducing tau phosphorylation levels has therapeutic potential; however, such approaches showed limited benefits. We sought to further develop our phosphorylation targeting chimera (PhosTAC) technology to specifically induce tau dephosphorylation. Herein, we use small molecule-based PhosTACs to recruit tau to PP2A, a native tau phosphatase. PhosTACs induced the formation of a stable ternary complex, leading to rapid, efficient, and sustained tau dephosphorylation, which also corr</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-18T22:01:33.474Z</modification><creation>2025-04-07T09:57:25.172Z</creation></dates><accession>S-EPMC11670127</accession><cross_references><pubmed>36753634</pubmed><doi>10.1021/jacs.2c11706</doi></cross_references></HashMap>